a Derpartment of Dermatology and Allergy , Ludwig-Maximilian-University , Munich , Germany.
Expert Rev Clin Pharmacol. 2018 May;11(5):467-474. doi: 10.1080/17512433.2018.1449642. Epub 2018 Mar 20.
Dupilumab is a new treatment option for patients with moderate-to-severe atopic dermatitis. It blocks IL-4/IL13-signaling and thereby inhibits receptor signaling downstream the JAK-STAT-pathway. Three of the main disease mechanisms of atopic dermatitis are affected by blocking this pathway; the decrease of skin barrier function, the class switch to IgE and the TH2-differentiation. Areas Covered: Dupilumab showed promising results in clinical trials of phase I-III. Clinical outcome parameters such as SCORAD, EASI, IGA and BSA improved with dupilumab. A positive effect on patient-reported outcomes like DLQI or pruritus-rating-scales was also demonstrated. The safety profile of dupilumab is superior to conventional immunosuppressive drugs, such as cyclosporine or methotrexate. Injection-site reactions and conjunctivitis were the most relevant side-effects. Skin infections were less frequently observed compared to placebo. Data on the use of dupilumab during pregnancy or in children are not published to date. Expert Commentary: Dupilumab was approved by the FDA in April 2017 for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
度普利尤单抗是一种治疗中重度特应性皮炎的新方法。它可阻断 IL-4/IL13 信号，从而抑制 JAK-STAT 通路下游的受体信号。特应性皮炎的三个主要发病机制通过阻断这条通路受到影响；皮肤屏障功能下降、IgE 类别转换和 TH2 分化。
度普利尤单抗在 I-III 期临床试验中显示出良好的效果。临床疗效参数，如 SCORAD、EASI、IGA 和 BSA，随着度普利尤单抗的应用而改善。患者报告结局如 DLQI 或瘙痒评分也显示出积极的效果。度普利尤单抗的安全性优于环孢素或甲氨蝶呤等传统免疫抑制剂。注射部位反应和结膜炎是最相关的副作用。与安慰剂相比，皮肤感染的发生率较低。
度普利尤单抗于 2017 年 4 月获得 FDA 批准，用于治疗中重度特应性皮炎的成人患者，这些患者的疾病经外用处方疗法治疗或不建议使用这些疗法后仍未得到充分控制。
